Corrigendum to “A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone”

Le résumé fourni par la source

The authors regret that in the original report some figures from previous studies are incorrectly given. The correct figures are as follows For "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 6% (25) with two grade 5 deaths (<1%).", read "The reported rate of pneumonitis in the most comparable trial population namely DESTINY-Breast02 was 10% (42) with two grade 5 deaths (<1%)." For "This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those without BM.", read "This intracranial therapeutic effect appears not to be limited to T-DXd, a pre-specified subgroup analysis of HER2CLIMB found in patients receiving tucatinib; the median OS was 21.6 months (95% CI 18.1-28.5 months) for those with BM versus 24.7 months (95% CI 21.6-28.9 months) for those with and without BM." The authors would like to apologise for any inconvenience caused. A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease aloneESMO OpenVol. 8Issue 6PreviewTrastuzumab deruxtecan (T-DXd) has demonstrated efficacy in patients with brain metastasis (BM), a group historically with poor outcomes. The prevalence of BMs in patients commencing T-DXd is currently unknown. No direct comparisons have been made of the activity of T-DXd in patients with active BM versus those with extracranial progression alone. This real-world study explored the prevalence of BMs in patients commencing T-DXd, the efficacy of T-DXd in active BM versus extracranial progression alone and the safety of T-DXd. Full-Text PDF Open Access

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.